 |
Research |
Our growing pipeline includes novel investigational medications for the potential treatment of life-threatening diseases in the areas of unmet medical need.
|
|
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on potential treatments in the following therapeutic areas: HIV/AIDS"Quad" Integrase STR (elvitegravir/FTC/TDF/cobicistat)
Potential Indication: HIV/AIDS U.S. and EU Approvals Submitted
Elvitegravir (integrase inhibitor)
Potential Indication: HIV/AIDS Phase 3
Cobicistat (formerly GS-9350) (PK enhancer)
Potential Indication: HIV/AIDS Phase 3
GS-7340 (nucleotide reverse transcriptase inhibitor)
Potential Indication: HIV/AIDS Phase 2
Liver DiseaseGS-7977 (nucleotide NS5B inhibitor)
Potential Indication: Hepatitis C Phase 3
GS-6624 (monoclonal antibody)
Potential Indication: Liver Fibrosis Phase 2
Tegobuvir/GS-9190 (non-nucleoside NS5B inhibitor)
Potential Indication: Hepatitis C Phase 2
GS-9256 (NS3 protease inhibitor)
Potential Indication: Hepatitis C Phase 2
GS-9451 (NS3 protease inhibitor)
Potential Indication: Hepatitis C Phase 2
GS-5885 (NS5A inhibitor)
Potential Indication: Hepatitis C Phase 2
GS-9620 (TLR-7 agonist)
Potential Indication: Hepatitis C / Hepatitis B Phase 1
GS-9669 (non-nucleoside polymerase inhibitor)
Potential Indication: Hepatitis C Phase 1
Cardiovascular/MetabolicRanolazine (late sodium current inhibitor)
Potential Indication: Incomplete Revascularization Post-PCI Phase 3
Ranolazine (late sodium current inhibitor)
Potential Indication: Potential Indication: Type 2 Diabetes Phase 3
RespiratoryAztreonam for Inhalation Solution
Potential Indication: Bronchiectasis Phase 3
GS-6624 (monoclonal antibody)
Potential Indication: Idiopathic Pulmonary Fibrosis Phase 1
Inflammation/OncologyGS-1101 (PI3K delta inhibitor)
Potential Indication: Chronic Lymphocytic Leukemia Phase 3
GS-1101 (PI3K delta inhibitor)
Potential Indication: Indolent non-Hodgkin’s Lymphoma Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Colorectal Cancer Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Myelofibrosis Phase 2
GS-6624 (monoclonal antibody)
Potential Indication: Pancreatic Cancer Phase 2
GS-9973 (Syk Inhibitor)
Potential Indication: Rheumatoid Arthritis Phase 1
|